11th Nov 2014 10:54
LONDON (Alliance News) - Circassia Pharmaceuticals PLC saw its shares rise Tuesday after it said it expects to complete recruitment into its phase III cat allergy product study, and complete its ragweed asthmatic safety study by the end of 2014.
In a statement, the specialty biopharmaceutical company focused on allergy products said positive results from the Ragweed-SPIRE study would enable inclusion of subjects with controlled asthma in the planned ragweed allergy phase III study, extending the target population to this group.
The company said it is also continuing phase III preparations for its grass allergy product candidate, Grass-SPIRE.
"Our phase III study in cat allergy remains on track, and we are successfully recruiting the experts we need to advance our broad portfolio and establish our commercial infrastructure," Chief Executive Steve Harris said.
"Encouraging results showing long-term symptom improvement in our grass allergy programme provide additional evidence of the potential benefits our treatments can offer allergy sufferers, while results from our controlled asthmatic study in house dust mite allergy further support the excellent safety profile we have seen with our product candidates to date," he added.
Circassia shares were up 3.3% at 293.00 pence Tuesday morning.
By Steve McGrath; [email protected]; @stevemcgrath1
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
CIR.L